Corgentech analgesic NDA tabbed for mid-’06
This article was originally published in Pharmaceutical Approvals Monthly
Corgentech plans to submit an NDA in mid-2006 for its needleless lidocaine injection system ALGRX 3268, the firm says Feb. 21. The product is targeted at children undergoing medical procedures requiring venipunctures and intravenous line placements. "With an onset of action of one to three minutes, ALGRX 3268 provides a unique fast-acting, local anesthetic for reducing pain associated with peripheral venous access and I.V. insertion procedures in children," the company says. Corgentech estimates approximately 18 mil. relevant procedures occur each year. 3268 is the first of three pain relievers Corgentech plans on filing...
You may also be interested in...
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.